Logo image of PDEX

PRO-DEX INC (PDEX) Stock Fundamental Analysis

USA - NASDAQ:PDEX - US74265M2052 - Common Stock

25.64 USD
-0.58 (-2.21%)
Last: 10/20/2025, 8:00:01 PM
25.6044 USD
-0.04 (-0.14%)
After Hours: 10/20/2025, 8:00:01 PM
Fundamental Rating

5

PDEX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. PDEX scores excellent on profitability, but there are some minor concerns on its financial health. PDEX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

PDEX had positive earnings in the past year.
In the past year PDEX has reported a negative cash flow from operations.
In the past 5 years PDEX has always been profitable.
In multiple years PDEX reported negative operating cash flow during the last 5 years.
PDEX Yearly Net Income VS EBIT VS OCF VS FCFPDEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M

1.2 Ratios

PDEX's Return On Assets of 14.74% is amongst the best of the industry. PDEX outperforms 95.79% of its industry peers.
PDEX has a Return On Equity of 24.30%. This is amongst the best in the industry. PDEX outperforms 96.84% of its industry peers.
PDEX's Return On Invested Capital of 18.00% is amongst the best of the industry. PDEX outperforms 96.32% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PDEX is significantly above the industry average of 8.88%.
The 3 year average ROIC (14.40%) for PDEX is below the current ROIC(18.00%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 14.74%
ROE 24.3%
ROIC 18%
ROA(3y)10.81%
ROA(5y)11.41%
ROE(3y)17.85%
ROE(5y)20.45%
ROIC(3y)14.4%
ROIC(5y)12.82%
PDEX Yearly ROA, ROE, ROICPDEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

PDEX has a Profit Margin of 13.50%. This is amongst the best in the industry. PDEX outperforms 90.53% of its industry peers.
In the last couple of years the Profit Margin of PDEX has declined.
PDEX has a better Operating Margin (16.04%) than 85.79% of its industry peers.
In the last couple of years the Operating Margin of PDEX has declined.
With a Gross Margin value of 29.30%, PDEX is not doing good in the industry: 76.32% of the companies in the same industry are doing better.
PDEX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 16.04%
PM (TTM) 13.5%
GM 29.3%
OM growth 3Y10.41%
OM growth 5Y-4.01%
PM growth 3Y7.45%
PM growth 5Y-5.12%
GM growth 3Y-2.11%
GM growth 5Y-4.93%
PDEX Yearly Profit, Operating, Gross MarginsPDEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

More info and screens

6

2. Health

2.1 Basic Checks

PDEX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for PDEX has been reduced compared to 1 year ago.
Compared to 5 years ago, PDEX has less shares outstanding
The debt/assets ratio for PDEX is higher compared to a year ago.
PDEX Yearly Shares OutstandingPDEX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
PDEX Yearly Total Debt VS Total AssetsPDEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

PDEX has an Altman-Z score of 5.19. This indicates that PDEX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PDEX (5.19) is better than 81.05% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that PDEX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.25, PDEX perfoms like the industry average, outperforming 55.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 5.19
ROIC/WACC2.22
WACC8.12%
PDEX Yearly LT Debt VS Equity VS FCFPDEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

PDEX has a Current Ratio of 3.13. This indicates that PDEX is financially healthy and has no problem in meeting its short term obligations.
PDEX has a Current ratio of 3.13. This is in the better half of the industry: PDEX outperforms 61.05% of its industry peers.
PDEX has a Quick Ratio of 1.67. This is a normal value and indicates that PDEX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of PDEX (1.67) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 1.67
PDEX Yearly Current Assets VS Current LiabilitesPDEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 309.68% over the past year.
PDEX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.96% yearly.
PDEX shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.67%.
Measured over the past years, PDEX shows a quite strong growth in Revenue. The Revenue has been growing by 13.84% on average per year.
EPS 1Y (TTM)309.68%
EPS 3Y35.1%
EPS 5Y10.96%
EPS Q2Q%-21.74%
Revenue 1Y (TTM)23.67%
Revenue growth 3Y16.57%
Revenue growth 5Y13.84%
Sales Q2Q%16.43%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.48%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PDEX Yearly Revenue VS EstimatesPDEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
PDEX Yearly EPS VS EstimatesPDEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2 2.5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 10.09 indicates a reasonable valuation of PDEX.
Compared to the rest of the industry, the Price/Earnings ratio of PDEX indicates a rather cheap valuation: PDEX is cheaper than 92.11% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of PDEX to the average of the S&P500 Index (27.69), we can say PDEX is valued rather cheaply.
A Price/Forward Earnings ratio of 10.56 indicates a reasonable valuation of PDEX.
PDEX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PDEX is cheaper than 92.63% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.18, PDEX is valued rather cheaply.
Industry RankSector Rank
PE 10.09
Fwd PE 10.56
PDEX Price Earnings VS Forward Price EarningsPDEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

PDEX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PDEX is cheaper than 94.74% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.34
PDEX Per share dataPDEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

The decent profitability rating of PDEX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.92
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PDEX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRO-DEX INC

NASDAQ:PDEX (10/20/2025, 8:00:01 PM)

After market: 25.6044 -0.04 (-0.14%)

25.64

-0.58 (-2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-04 2025-09-04/amc
Earnings (Next)10-30 2025-10-30
Inst Owners32.91%
Inst Owner Change0.05%
Ins Owners35.95%
Ins Owner Change0%
Market Cap84.10M
Analysts82.86
Price Target57.12 (122.78%)
Short Float %12.42%
Short Ratio6.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.07%
Min EPS beat(2)-24.91%
Max EPS beat(2)71.05%
EPS beat(4)3
Avg EPS beat(4)64.27%
Min EPS beat(4)-24.91%
Max EPS beat(4)153.55%
EPS beat(8)4
Avg EPS beat(8)3.28%
EPS beat(12)6
Avg EPS beat(12)4.51%
EPS beat(16)7
Avg EPS beat(16)5.14%
Revenue beat(2)0
Avg Revenue beat(2)-3.86%
Min Revenue beat(2)-4.18%
Max Revenue beat(2)-3.54%
Revenue beat(4)2
Avg Revenue beat(4)8.06%
Min Revenue beat(4)-4.18%
Max Revenue beat(4)20.66%
Revenue beat(8)6
Avg Revenue beat(8)11.15%
Revenue beat(12)9
Avg Revenue beat(12)10.3%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 10.09
Fwd PE 10.56
P/S 1.26
P/FCF N/A
P/OCF N/A
P/B 2.34
P/tB 2.34
EV/EBITDA 7.34
EPS(TTM)2.54
EY9.91%
EPS(NY)2.43
Fwd EY9.47%
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS20.3
BVpS10.98
TBVpS10.97
PEG (NY)N/A
PEG (5Y)0.92
Profitability
Industry RankSector Rank
ROA 14.74%
ROE 24.3%
ROCE 23.22%
ROIC 18%
ROICexc 21.32%
ROICexgc 21.34%
OM 16.04%
PM (TTM) 13.5%
GM 29.3%
FCFM N/A
ROA(3y)10.81%
ROA(5y)11.41%
ROE(3y)17.85%
ROE(5y)20.45%
ROIC(3y)14.4%
ROIC(5y)12.82%
ROICexc(3y)16.89%
ROICexc(5y)14.77%
ROICexgc(3y)16.92%
ROICexgc(5y)14.81%
ROCE(3y)18.57%
ROCE(5y)16.54%
ROICexcg growth 3Y25.53%
ROICexcg growth 5Y-7.62%
ROICexc growth 3Y25.63%
ROICexc growth 5Y-7.46%
OM growth 3Y10.41%
OM growth 5Y-4.01%
PM growth 3Y7.45%
PM growth 5Y-5.12%
GM growth 3Y-2.11%
GM growth 5Y-4.93%
F-Score6
Asset Turnover1.09
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 0.78
Cap/Depr 100.81%
Cap/Sales 1.88%
Interest Coverage 13.02
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 1.67
Altman-Z 5.19
F-Score6
WACC8.12%
ROIC/WACC2.22
Cap/Depr(3y)99.45%
Cap/Depr(5y)344.31%
Cap/Sales(3y)1.94%
Cap/Sales(5y)6.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)309.68%
EPS 3Y35.1%
EPS 5Y10.96%
EPS Q2Q%-21.74%
EPS Next Y-4.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.67%
Revenue growth 3Y16.57%
Revenue growth 5Y13.84%
Sales Q2Q%16.43%
Revenue Next Year4.48%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y48.95%
EBIT growth 3Y28.7%
EBIT growth 5Y9.27%
EBIT Next Year10.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-155.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.99%
OCF growth 3YN/A
OCF growth 5YN/A